Future microbiology · 2025
Evaluation of a bivalent vaccine composed of iron scavenger receptors PMI1426 and PMI1945 against Proteus mirabilis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohammadzadeh Roghayeh, Habibi Mehri, Asadi Karam Mohammad Reza
Аннотация
AIM: Urinary tract infections (UTIs) caused by Proteus mirabilis are common infectious diseases. Currently, no vaccine is available against UTIs, making the development of an effective vaccine a critical goal to reduce the prevalence and antibiotic resistance of UTIs. Hence, we have investigated the immunogenicity and protective potential of a bivalent vaccine candidate comprising the iron scavenger receptors PMI1426 and PMI1945 from P. mirabilis in mice.
METHODS: In this study, vaccine candidates composed of PMI1426 and PMI1945 from P. mirabilis were developed, and their immunogenicity, efficacy, and synergistic effects were evaluated in mice.
RESULTS: Serum levels of IgG, IgG isotypes, IgA, and urinary IgA, as well as cytokine levels including IFN-γ, IL-4, and IL-17 were significantly elevated following vaccination with PMI1426 and PMI1945 as compared to the controls. The addition of alum enhanced the immune responses in both single and combined vaccine formulations. Furthermore, bacterial colonization in the bladder of mice challenged with P. mirabilis was significantly reduced in mice received the proteins admixed with alum compared to control groups.
CONCLUSION: Our results support the development of a promising vaccine candidate against P. mirabilis UTIs. Future human clinical trials are needed to validate the efficacy and safety of the vaccine candidates.
METHODS: In this study, vaccine candidates composed of PMI1426 and PMI1945 from P. mirabilis were developed, and their immunogenicity, efficacy, and synergistic effects were evaluated in mice.
RESULTS: Serum levels of IgG, IgG isotypes, IgA, and urinary IgA, as well as cytokine levels including IFN-γ, IL-4, and IL-17 were significantly elevated following vaccination with PMI1426 and PMI1945 as compared to the controls. The addition of alum enhanced the immune responses in both single and combined vaccine formulations. Furthermore, bacterial colonization in the bladder of mice challenged with P. mirabilis was significantly reduced in mice received the proteins admixed with alum compared to control groups.
CONCLUSION: Our results support the development of a promising vaccine candidate against P. mirabilis UTIs. Future human clinical trials are needed to validate the efficacy and safety of the vaccine candidates.